Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Edit custom filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2015 1
2016 2
2017 2
2018 4
2019 2
2020 3
2022 2
2024 3
2025 1
2026 2

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

19 results

Results by year

Filters applied: . Clear all
Page 1
A Review of Pharmacologic and Non-Pharmacologic Therapies in the Management of Irritable Bowel Syndrome: Current Recommendations and Evidence.
Papale AJ, Flattau R, Vithlani N, Mahajan D, Nadella S. Papale AJ, et al. J Clin Med. 2024 Nov 18;13(22):6948. doi: 10.3390/jcm13226948. J Clin Med. 2024. PMID: 39598092 Free PMC article. Review.
IBS is classified into several subtypes based on predominant presenting symptoms, including IBS with constipation (IBS-C) and IBS with diarrhea (IBS-D), with each requiring targeted approaches to treatment. Some treatments, such as psychotherapy, dietary inte …
IBS is classified into several subtypes based on predominant presenting symptoms, including IBS with constipation (IBS-C) and IBS with diarr …
Novel Therapies in IBS-D Treatment.
Nee J, Zakari M, Lembo AJ. Nee J, et al. Curr Treat Options Gastroenterol. 2015 Dec;13(4):432-40. doi: 10.1007/s11938-015-0068-5. Curr Treat Options Gastroenterol. 2015. PMID: 26432092
There are currently 3 FDA-approved treatments for IBS-D, which have been shown to improve both abdominal pain and diarrhea. Alosetron was initially approved by FDA 2000; however, its use is now limited to women with severe IBS-D symptoms refractory to …
There are currently 3 FDA-approved treatments for IBS-D, which have been shown to improve both abdominal pain and diarrhea. Al …
[Treatment of Irritable Bowel Syndrome with Predominant Diarrhea].
Kim MC, Park Y, Lee HS; Korean Society of Neurogastroenterology and Motility. Kim MC, et al. Korean J Gastroenterol. 2025 Apr 25;85(2):105-109. doi: 10.4166/kjg.2025.011. Korean J Gastroenterol. 2025. PMID: 40276826 Free PMC article. Review. Korean.
Irritable bowel syndrome with predominant diarrhea (IBS-D) is a subtype of irritable bowel syndrome that causes frequent loose stools. Although the precise pathophysiology remains unclear, factors, such as gut microbiota imbalance, visceral hypersensitivity, intesti …
Irritable bowel syndrome with predominant diarrhea (IBS-D) is a subtype of irritable bowel syndrome that causes frequent loose …
Review article: an analysis of safety profiles of treatments for diarrhoea-predominant irritable bowel syndrome.
Lacy BE. Lacy BE. Aliment Pharmacol Ther. 2018 Oct;48(8):817-830. doi: 10.1111/apt.14948. Epub 2018 Sep 7. Aliment Pharmacol Ther. 2018. PMID: 30194692 Free PMC article. Review.
AIM: To provide an overview of the safety of interventions that may be used to manage patients with diarrhoea-predominant IBS (IBS-D). METHODS: Medline and Embase database searches (through 02 May 2018) to identify clinical studies that evaluated treatment safety an …
AIM: To provide an overview of the safety of interventions that may be used to manage patients with diarrhoea-predominant IBS (IBS- …
New treatment options for irritable bowel syndrome with predominant diarrhea.
Weber HC. Weber HC. Curr Opin Endocrinol Diabetes Obes. 2017 Feb;24(1):25-30. doi: 10.1097/MED.0000000000000302. Curr Opin Endocrinol Diabetes Obes. 2017. PMID: 27875419 Review.
In addition to previously introduced pharmacological treatment modalities for IBS with constipation (IBS-C) with synthetic peptides and small molecules targeting gastrointestinal receptors and ion channels, the newly Food and Drug Administration-approved mixed peripheral o …
In addition to previously introduced pharmacological treatment modalities for IBS with constipation (IBS-C) with synthetic peptides and smal …
Journal of Clinical Gastroenterology Lectureship Dubai 2022 : Management of Irritable Bowel Syndrome With Diarrhea.
Marasco G, Cremon C, Barbaro MR, Stanghellini V, Barbara G. Marasco G, et al. J Clin Gastroenterol. 2024 Mar 1;58(3):221-231. doi: 10.1097/MCG.0000000000001964. J Clin Gastroenterol. 2024. PMID: 38227850
Irritable bowel syndrome (IBS) with diarrhea (IBS-D) affects ~1% of the general population and is characterized by abdominal pain associated with diarrhea. IBS-D symptoms significantly impact the quality of life of patients. Major uncertainties remain …
Irritable bowel syndrome (IBS) with diarrhea (IBS-D) affects ~1% of the general population and is characterized by abdominal p …
Review: The Role of MOP and DOP Receptors in Treatment of Diarrheapredominant Irritable Bowel Syndrome.
Jarmuż A, Zielińska M, Leń K, Banaszek M, Storr M, Fichna J. Jarmuż A, et al. Mini Rev Med Chem. 2016;16(18):1462-1469. doi: 10.2174/1389557516666160804165318. Mini Rev Med Chem. 2016. PMID: 27494159 Review.
IBS-D is associated with numerous symptoms including diarrhea, bloating, abdominal pain and discomfort, which significantly reduce patients' quality of life. Due to a complex and unclear pathogenesis, effective therapy against IBS-D has not been develo …
IBS-D is associated with numerous symptoms including diarrhea, bloating, abdominal pain and discomfort, which significantly re …
Current US Food and Drug Administration-Approved Pharmacologic Therapies for the Treatment of Irritable Bowel Syndrome with Diarrhea.
Brenner DM, Sayuk GS. Brenner DM, et al. Adv Ther. 2020 Jan;37(1):83-96. doi: 10.1007/s12325-019-01116-z. Epub 2019 Nov 9. Adv Ther. 2020. PMID: 31707713 Review.
Pharmacologic agents currently approved by the US Food and Drug Administration for treatment of IBS with diarrhea (IBS-D) in adults are the nonsystemic antibiotic rifaximin, the mixed - and kappa-opioid receptor agonist/delta-opioid antagonist eluxadoline, a …
Pharmacologic agents currently approved by the US Food and Drug Administration for treatment of IBS with diarrhea (IBS-D) in a …
Drugs of the future for diarrhea-predominant irritable bowel syndrome: an overview of current investigational drugs.
Mozaffari S, Nikfar S, Abdollahi M. Mozaffari S, et al. Expert Opin Investig Drugs. 2024 Mar;33(3):219-228. doi: 10.1080/13543784.2024.2320703. Epub 2024 Feb 23. Expert Opin Investig Drugs. 2024. PMID: 38366822 Review.
Clinical trial evidence has shown that loperamide, eluxadoline, alosetron, ramosetron, bile acid sequestrants, and rifaximin can modulate GI alterations and benefit patients with IBS-D. Among the potential therapies, ibodutant, ibudilast, blautix, BOS-589, so …
Clinical trial evidence has shown that loperamide, eluxadoline, alosetron, ramosetron, bile acid sequestrants, and rifaximin can modu …
Update on the Management of Diarrhea-Predominant Irritable Bowel Syndrome: Focus on Rifaximin and Eluxadoline.
Rivkin A, Rybalov S. Rivkin A, et al. Pharmacotherapy. 2016 Mar;36(3):300-16. doi: 10.1002/phar.1712. Epub 2016 Mar 11. Pharmacotherapy. 2016. PMID: 26971716 Review.
All of these options have limited efficacy in managing IBS-D. Rifaximin, a nonabsorbable antibiotic, has been evaluated in patients with IBS-D. ...This review evaluates evidence for the use of rifaximin and eluxadoline in patients with …
All of these options have limited efficacy in managing IBS-D. Rifaximin, a nonabsorbable antibiotic, has been evaluated …
19 results